We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -256.00 | -2.14% | 11,708.00 | 11,710.00 | 11,716.00 | 11,908.00 | 11,678.00 | 11,844.00 | 2,989,208 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5371 | 25.82 | 185.51B |
From Feb 2020 to Feb 2025
TIDMAZN
RNS Number : 6199I
AstraZeneca PLC
01 September 2016
01 September 2016 07:00 BST
ASTRAZENECA COMPLETES COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIO
AstraZeneca today announced that it has completed* the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest). As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment (to be recognised in the third quarter of 2016), along with all future milestone and royalty payments, will be reported as Externalisation Revenue in the Company's financial statements.
* With the exception of Ukraine and Zimbabwe, which are subject to separate closing
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Hot Features
Premium
Media Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
+46 8 553 260
Jacob Lund Sweden 20
Michele Meixell US +1 302 885 2677
Investor Relations
UK
Thomas Kudsk
Larsen +44 203 749 5712
Finance, Fixed +44 7881 615
Craig Marks Income, M&A 764
Respiratory &
Nick Stone Autoimmunity +44 203 749 5716
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris Infection & Neuroscience +44 203 749 5711
US
Cardiovascular
Lindsey Trickett & Metabolic Diseases +1 240 543 7970
Mitchell Chan Oncology +1 240 477 3771
Toll-free +1 866 381 7277
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRAKDDNABKDQFN
(END) Dow Jones Newswires
September 01, 2016 02:00 ET (06:00 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
